@article {Thakur2021.03.16.21253167, author = {Kiran T. Thakur and Emily Happy Miller and Michael D. Glendinning and Osama Al-Dalahmah and Matei A. Banu and Amelia K. Boehme and Alexandra L. Boubour and Samuel L. Bruce and Alexander M. Chong and Jan Claassen and Phyllis L. Faust and Gunnar Hargus and Richard Hickman and Sachin Jambawalikar and Alexander G. Khandji and Carla Y. Kim and Robyn S. Klein and Angela Lignelli-Dipple and Chun-Chieh Lin and Yang Liu and Michael L. Miller and Gul Moonis and Anna S. Nordvig and Jonathan B. Overdevest and Morgan L. Prust and Serge Przedborski and William H. Roth and Allison Soung and Kurenai Tanji and Andrew F. Teich and Dritan Agalliu and Anne-Catrin Uhlemann and James E. Goldman and Peter Canoll}, title = {COVID-19 Neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital}, elocation-id = {2021.03.16.21253167}, year = {2021}, doi = {10.1101/2021.03.16.21253167}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Many patients with SARS-CoV-2 infection develop neurological signs and symptoms, though, to date, little evidence exists that primary infection of the brain is a significant contributing factor. We present the clinical, neuropathological, and molecular findings of 41 consecutive patients with SARS-CoV-2 infections who died and underwent autopsy in our medical center. The mean age was 74 years (38-97 years), 27 patients (66\%) were male and 34 (83\%) were of Hispanic/Latinx ethnicity. Twenty-four patients (59\%) were admitted to the intensive care unit (ICU). Hospital-associated complications were common, including 8 (20\%) with deep vein thrombosis/pulmonary embolism (DVT/PE), 7 (17\%) patients with acute kidney injury requiring dialysis, and 10 (24\%) with positive blood cultures during admission. Eight (20\%) patients died within 24 hours of hospital admission, while 11 (27\%) died more than 4 weeks after hospital admission. Neuropathological examination of 20-30 areas from each brain revealed hypoxic/ischemic changes in all brains, both global and focal; large and small infarcts, many of which appeared hemorrhagic; and microglial activation with microglial nodules accompanied by neuronophagia, most prominently in the brainstem. We observed sparse T lymphocyte accumulation in either perivascular regions or in the brain parenchyma. Many brains contained atherosclerosis of large arteries and arteriolosclerosis, though none had evidence of vasculitis. Eighteen (44\%) contained pathologies of neurodegenerative diseases, not unexpected given the age range of our patients. We examined multiple fresh frozen and fixed tissues from 28 brains for the presence of viral RNA and protein, using quantitative reverse-transcriptase PCR (qRT-PCR), RNAscope, and immunocytochemistry with primers, probes, and antibodies directed against the spike and nucleocapsid regions. qRT-PCR revealed low to very low, but detectable, viral RNA levels in the majority of brains, although they were far lower than those in nasal epithelia. RNAscope and immunocytochemistry failed to detect viral RNA or protein in brains. Our findings indicate that the levels of detectable virus in COVID-19 brains are very low and do not correlate with the histopathological alterations. These findings suggest that microglial activation, microglial nodules and neuronophagia, observed in the majority of brains, do not result from direct viral infection of brain parenchyma, but rather likely from systemic inflammation, perhaps with synergistic contribution from hypoxia/ischemia. Further studies are needed to define whether these pathologies, if present in patients who survive COVID-19, might contribute to chronic neurological problems.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAll funding supporting the work is acknowledged in the manuscript, and includes the following: Encephalitis and COVID-19 Seed Funding Award provided by the Encephalitis Society (EHM) NS106014, supplement (JC) NIH/NINDS 1K23NS105935-01 (KTT) Generous gift from Dr. Yechiam Yemini (S.P.) Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Columbia University Irving Medical Center (CUIMC) Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is presented in the manuscript and supplementary figures and tables are included in our submission. There are no external datasets.}, URL = {https://www.medrxiv.org/content/early/2021/03/20/2021.03.16.21253167}, eprint = {https://www.medrxiv.org/content/early/2021/03/20/2021.03.16.21253167.full.pdf}, journal = {medRxiv} }